RTW Investments’s Sarepta Therapeutics SRPT Stock Holding History

RTW Investments’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-582,265	Closed	-$52.4M	–	119
2021 Q4	$52.4M	Buy	+582,265	New	+$49.8M	0.77%	40
2020 Q2	–	Sell	-529,261	Closed	-$51.8M	–	79
2020 Q1	$51.8M	Sell	529,261 -76,501	-13%	-$8.74M	2.23%	15
2019 Q4	$78.2M	Sell	605,762 -118,549	-16%	-$12M	2.95%	10
2019 Q3	$54.6M	Buy	724,311 +120,075	+20%	+$14.2M	3.24%	10
2019 Q2	$91.8M	Buy	604,236 +266,037	+79%	+$32.3M	4.9%	6
2019 Q1	$40.3M	Sell	338,199 -27,712	-8%	-$3.56M	2.75%	12
2018 Q4	$39.9M	Buy	365,911 +51,841	+17%	+$6.48M	3.66%	8
2018 Q3	$50.7M	Sell	314,070 -664,481	-68%	-$90.8M	3.04%	9
2018 Q2	$129M	Buy	978,551 +290,280	+42%	+$27.4M	9.33%	4
2018 Q1	$51M	Buy	+688,271	New	+$45.9M	4.85%	5

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments's SRPT Position: Q1 2022 in Review

RTW Investments sold out of Sarepta Therapeutics (SRPT) in Q1 2022, closing a stake of 582,265 shares — an estimated $52.4M sold.

RTW Investments first reported a position in SRPT in Q1 2018 and held it in 10 quarters. The position peaked at $129M in Q2 2018. 328 funds tracked by Wall St. Rank hold SRPT as of Q1 2022.

RTW Investments reported no remaining Sarepta Therapeutics position as of Q1 2022 after selling out during the quarter.
RTW Investments sold 582,265 Sarepta Therapeutics shares in Q1 2022, an estimated $52.4M.
RTW Investments first reported a position in Sarepta Therapeutics in Q1 2018 and held it in 10 quarters.
RTW Investments's Sarepta Therapeutics position peaked at $129M in Q2 2018.
328 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2022.

Based on RTW Investments's 13F filing for Q1 2022, filed 16 May 2022.